While we observed a correlation between increased ERK3 expression and the HER2+ subtype, these are very distinct types of breast cancer (HER2+ vs. TNBC), with distinct disturbances in molecular signalling, treatment responses, and overall cell behaviour (39). This evidence concerns the gene MAPK12 and breast carcinoma.